Which One is More Effective, Filgrastim or Lenograstim, During Febrile Neutropenia Attack in Hospitalized Patients with Solid Tumors?

  • Sonmez, Ozlem Uysal (Department of Medical Oncology, Yeditepe University Hospital) ;
  • Guclu, Ertugrul (Department of Clinical Microbiology, Sakarya University) ;
  • Uyeturk, Ummugul (Department of Medical Oncology, Abant Izzet Baysal University) ;
  • Esbah, Onur (Department of Medical Oncology, Dr.Abdurahman Yurtarslan Oncology Hospital) ;
  • Turker, Ibrahim (Department of Medical Oncology, Dr.Abdurahman Yurtarslan Oncology Hospital) ;
  • Bal, Oznur (Department of Medical Oncology, Dr.Abdurahman Yurtarslan Oncology Hospital) ;
  • Budakoglu, Burcin (Department of Medical Oncology, Dr.Abdurahman Yurtarslan Oncology Hospital) ;
  • Arslan, Ulku Yalcintas (Department of Medical Oncology, Dr.Abdurahman Yurtarslan Oncology Hospital) ;
  • Karabay, Oguz (Department of Clinical Microbiology, Sakarya University) ;
  • Oksuzoglu, Berna (Department of Medical Oncology, Dr.Abdurahman Yurtarslan Oncology Hospital)
  • Published : 2015.03.04


Background: Chemotherapy-induced febrile neutropenia (FN) with solid tumors causes mortality and morbidity at a significant rate. The purpose of this study was to compare the effects of filgastrim and lenograstim started with the first dose of antibiotics in hospitalized patients diagnosed with FN. Materials and Methods: Between February 2009 and May 2012, 151 patients diagnosed with FN were evaluated, retrospectively. In those considered appropriate for hospitalization, convenient antibiotic therapy with granulocyte colony stimulating factors was started within first 30 minutes by completing necessary examinations in accordance with FEN guide recommendations. Results: In this study, 175 febrile neutropenia attacks in 151 patients were examined. Seventy three of the patients were male and 78 were female. The average age was 53.6 and 53.6, respectively. The most common solid tumor was breast carcinoma in 38 (25%). One hundred and five FN patients (58%) were those who received granulocyte colony stimulating factors as primary prophylaxis. Conclusions: While studies comparing both drugs generally involve treatments started for prophylaxis, this study compared the treatment given during the febrile neutropenia attack. Compared to lenograstim, filgastrim shortens the duration of hospitalization during febrile neutropenia attack by facilitating faster recovery with solid tumors.


  1. Aapro MS, Bohlius J, Cameron DA, et al (2011). European organization for research and treatment of cancer. 2010 update of EORTC guidelines for the use of granulocytecolony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumors. Eur J Cancer, 47, 8-32.
  2. Clark OA, Lyman GH, Castro AA, et al (2005). Colonystimulating factors for chemotherapy-induced febrile neutropenia: a meta-analysis of randomized controlled trials. J Clin Oncol, 23, 4198-214.
  3. Cooper KL, Madan J, Whyte S, et al (2011). Granulocyte colonystimulating factors for febrile neutropenia prophylaxis following chemotherapy: systematic review and metaanalysis. BMC Cancer, 11, 404
  4. Craig A, Mai J, Cai S, et al (2009). Neutrophil recruitment to the lungs during bacterial pneumonia. Infect Immun, 77, 568-75.
  5. Freifeld AG, Bow EJ, Sepkowitz KA, et al (2011). Infectious diseases society of america. clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis, 52, 56-93.
  6. Fontanella C, Bolzonello S, Lederer B, Aprile G (2014). Management of breast cancer patients with chemotherapyinduced neutropenia or febrileneutropenia. Breast Care (Basel), 9, 239-45
  7. Gardellini A, Gigli F, Babic A, et al (2013). Filgrastim XM02 (Tevagrastim$^{(R)}$) after autologous stem cell transplantation compared to lenograstim: favorable cost-efficacy analysis. Ecancermedicalscience, 7, 327.
  8. Hughes WT, Armstrong D, Bodey GP, et al (2002). Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis, 34, 730-51.
  9. Kim IH, Park SK, Suh OK, et al (2003). Comparison of lenogastrim and filgastrim on haematological effects after autologous peripheral blood stem cell transplantation with high-dose chemotherapy. Current Med Res Opinion, 19, 753-59
  10. Orciuolo E, Buda G, Marturano E, et al (2011). Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization. Leuk Res, 35, 899-903.
  11. Osmani AH, Ansari TZ, Masood N, et al (2012). Outcome of febrile neutropenic patients on granulocyte colony stimulating factor in a tertiary care hospital. Asian Pac J Cancer Prev, 13, 2523-26.
  12. Procopio G, Niger M, Testa I (2011). Lecture: management of chemotherapy-induced febrile neutropenia; guidelines and colony stimulating factors. Neurol Sci, 2, 217-19.
  13. Sari N, Dalva K, Ilhan IE (2013). Comparison of filgrastim and lenograstim in pediatric solid tumors. Pediatr Hematol Oncol, 30, 655-61
  14. Serkan Keskin E (2012). The use of high-dose chemotherapy and hematopoietic growth factors. In Mandel NM, Onat H(ed): Cancer Patient Approach. (2nd ed) Istanbul, Nobel Tip Kitabevi, 15, 155-61 (in Turkish)..